Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

IHE tracks the Dow Jones U.S. Select Pharmaceuticals Index and holds 59 pharmaceutical names with an annual expense charge of 0.38%. The fund’s return comes from dividend income from mature U.S. drugmakers and from price appreciation tied to pipeline catalysts and blockbuster launches. Eli Lilly and Johnson & Johnson drive a large share of holdings, creating concentration risk that makes the ETF behave like a two-stock bet. The fund’s beta is 0.50, indicating lower volatility than the broad market, but it can still move sharply when major holdings react to clinical or commercial developments. Recent performance shows strong gains versus healthcare benchmarks, including a 38% one-year return versus 9% for XLV, and a positive 2026 year-to-date gap.

"Trump signed his "most favored nation" drug pricing executive order last May, tying what Medicare pays to lower prices in other developed countries, and IHE has since rallied 38% over twelve months to roughly $89. So the real question for retirement investors is whether IHE has already absorbed the policy hit, or whether the actual margin compression is still ahead of the ETF."

"IHE tracks the Dow Jones U.S. Select Pharmaceuticals Index, holding 59 names with charges of 0.38% a year. The return engine is straightforward. You collect dividends from a basket of mature U.S. drugmakers (the most recent quarterly distribution was $0.2845 per share) and you ride pipeline catalysts when blockbusters land. Eli Lilly ( NYSE:LLY | LLY Price Prediction) and its tirzepatide franchise is the obvious one."

"The catch is concentration. Johnson & Johnson and Eli Lilly together account for 42% of the fund, which means IHE is closer to a two-stock bet with 57 chaperones than a diversified pharma sleeve. Beta sits at 0.50, so volatility is genuinely lower than the broad market, but that statistic flatters the fund. When LLY moves on a GLP-1 data readout, IHE moves with it."

"Over the past year, while Trump's MFN order was being drafted, signed, and litigated, IHE returned 38%. The broader Health Care Select Sector SPDR, Health Care Select Sector SPDR Fund ( NYSEARCA:XLV), returned 9% over the same window. Year-to-date in 2026, the gap is even more telling. IHE is up 4% while XLV is down 5%."

Read at 24/7 Wall St.